罗氏超10亿美元从荃信生物获得临床前呼吸系统双抗

Minhua笔记
Oct 31

罗氏与荃信生物达成全球授权许可协议,以7500万美元首付款加最高9.95亿美元里程金,总价值超10亿美元获得临床前呼吸系统疾病双抗QX031N的全球独家权益。据10月28日提交给香港联交所的文件,罗氏已与荃信生物签署一项全球授权许可协议,获得QX031N的开发和商业化权。该抗体药物靶向两种关键炎症蛋白。根据协议,罗氏在全球范围内独家拥有开发和商业化QX031N的权利,荃信生物将获得7500万美元的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10